Extract
We thank A. Havette and co-workers for the interest shown in our article [1]. They suggest that the benefit of itraconazole–prednisolone combination in allergic bronchopulmonary aspergillosis (ABPA) may be due to the increased bioavailability of inhaled corticosteroids (ICS) resulting from the CYP3A4 inhibition by itraconazole. While theoretically correct, there is no evidence that the interaction with ICS mediates the beneficial effect of itraconazole. Moreover, none of the previous trials of oral triazoles in ABPA have explored this aspect [2–5]. Our recent study suggests that itraconazole is likely beneficial when combined with prednisolone. Whether ICS potentiates this synergy remains to be seen. A. Havette and co-workers further indicate that discontinuing itraconazole and oral steroids at 4 months in the combination arm could have diminished the problem of ICS–itraconazole interaction. We, however, feel that the best study design to investigate the actual effect of prednisolone–itraconazole combination would be to use the combination in ABPA sans asthma, where ICS are not routinely used [6].
Abstract
好处大于使用泼尼松龙 - 肾上腺唑酮治疗ABPA使哮喘复杂化的风险https://bit.ly/3oyX53I
脚注
利益冲突:R。Agarwal无需透露。
Conflict of interest: V. Muthu has nothing to disclose.
- 已收到November 22, 2021.
- Accepted2021年11月28日。
- 版权所有©作者2022。用于复制权和权限联系permissions{at}ersnet.org